Abstract:OBJECTIVE:To evaluate the immunogenicity, safety, and dosage of a new inactivated hepatitis A vaccine administered to young adults.METHODS:One hundred and four normal adult volunteers, seronegative for hepatitis A virus and hepatitis B surface antigen, were randomly assigned to one of three groups. The high-dose group received a primary dose of 1000 units of the new vaccine, the low-dose group received a primary dose of 500 units of the same vaccine, and the Havrix group received a primary dose of 1440 enzyme-linked immunosorbent assay units of Havrix, a licensed inactivated hepatitis A vaccine. All groups received a booster dose of the same vaccine 6 months after the primary dose. Local and systemic adverse reactions, seroconversion rates, and geometric mean titers of hepatitis A virus antibodies were measured in all three groups.RESULTS:Local and systemic reaction types and rates were similar in all three groups after primary and booster doses, although local reactions were more frequent in the Havrix group following the primary dose. No serious adverse reactions occurred. One month after the primary dose, the seroconversion rate was 87.5% in the high-dose group, 70.0% in the low-dose group, and 50.0% in the Havrix group (P = 0.001, versus the high-dose group). At month 6 (before administration of the booster dose), seroconversion rates were 96.9% in the high-dose group, 65.0% in the low-dose group (P = 0.0029), and 68.8% in the Havrix group (P = 0.007). All subjects in all groups seroconverted by one month after receipt of the booster dose. Geometric mean titers were similar in all three groups at month 1, but were higher in the high-dose group (264 mIU/ml) than those in the Havrix group (135 mIU/ml) at month 6 (P = 0.0013). One month after the booster dose, geometric mean titers in the high-dose group (2747 mIU/ml) were higher than those in the low-dose group (1657 mIU/ml) (P = 0.0223) or in the Havrix group (1316 mIU/ml) (P = 0.01).CONCLUSIONS:This new inactivated hepatitis A vaccine is immunogenic and safe; two doses of either 500 or 1000 units can induce hepatitis A virus antibodies well above the protection level.

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

The Response of Hepatitis B Vaccination on Seronegative Adults with Different Vaccination Schedules.

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

SAFETY AND IMMUNOGENICITY OF A COMBINED HEPATITIS A AND B VACCINE IN RECRUITS

Comparison of Hepatitis B Surface Antibody Levels After Vaccination With Combined One Dose of Hexavalent Vaccine and Two Doses of Pentavalent Vaccine Versus Three Doses of Pentavalent Vaccine

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Antibody reaction to immunization with recombinant hepatitis B vaccine in undergraduates

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Mainly from the Rural Areas of Western China and Born Before HBV Vaccination Integrated into Expanded Program of Immunization.

Immunological Effects of a 10-Μg Dose of Domestic Hepatitis B Vaccine in Adults

Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Factors influencing immunologic response to hepatitis B vaccine in adults

Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults

Immune response to one booster dose of inactivated hepatitis A vaccine in college students

Requirement for Further Validation on the Seroconversion of Hepatitis B Surface Antigen in Successful Vaccinees.

Comparison of the effectiveness four years after Homo/Hetero prime-boost with 10 μg HP and 20 μg CHO recombinant hepatitis B vaccine at 1 and 6 months in maternal HBsAg-negative children

Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study.

Safety and Immunogenicity of a New Inactivated Hepatitis A Vaccine

[Safety and Immunogenicity of a New Inactivated Hepatitis A Vaccine].